CSS
CPRX icon

Cubist Systematic Strategies’s Catalyst Pharmaceutical CPRX Stock Holding History

Cubist Systematic Strategies’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,523
Closed -$132K – 3053
2024
Q2 		$132K Sell
8,523
-233,967
-96% -$3.64M ﹤0.01% 2584
2024
Q1 		$3.87M Buy
242,490
+197,232
+436% +$2.97M 0.02% 1138
2023
Q4 		$761K Buy
45,258
+24,452
+118% +$334K ﹤0.01% 2271
2023
Q3 		$243K Buy
+20,806
New +$278K ﹤0.01% 2694
2023
Q2 		– Sell
-189,495
Closed -$3.14M – 3630
2023
Q1 		$3.14M Sell
189,495
-142,919
-43% -$2.36M 0.02% 1304
2022
Q4 		$6.18M Sell
332,414
-309,386
-48% -$4.76M 0.04% 834
2022
Q3 		$8.23M Buy
641,800
+287,281
+81% +$3.4M 0.05% 628
2022
Q2 		$2.48M Buy
354,519
+54,924
+18% +$403K 0.02% 1652
2022
Q1 		$2.48M Sell
299,595
-42,167
-12% -$298K 0.02% 1303
2021
Q4 		$2.31M Buy
341,762
+229,567
+205% +$1.51M 0.02% 1235
2021
Q3 		$595K Buy
112,195
+52,140
+87% +$285K 0.01% 1911
2021
Q2 		$345K Buy
60,055
+29,888
+99% +$154K ﹤0.01% 2247
2021
Q1 		$139K Sell
30,167
-1,166
-4% -$4.63K ﹤0.01% 2579
2020
Q4 		$105K Sell
31,333
-8,242
-21% -$27.7K ﹤0.01% 2401
2020
Q3 		$118K Sell
39,575
-212
-0.5% -$829 ﹤0.01% 2254
2020
Q2 		$184K Buy
+39,787
New +$179K ﹤0.01% 2061
2020
Q1 		– Sell
-27,143
Closed -$102K – 2206
2019
Q4 		$102K Buy
+27,143
New +$127K ﹤0.01% 2185
2019
Q3 		– Sell
-81,806
Closed -$314K – 2250
2019
Q2 		$314K Buy
+81,806
New +$353K 0.01% 1768
2018
Q2 		– Sell
-12,835
Closed -$31K – 1832
2018
Q1 		$31K Buy
+12,835
New +$42.7K ﹤0.01% 1731
2017
Q2 		– Sell
-11,500
Closed -$22K – 1704
2017
Q1 		$22K Buy
+11,500
New +$14.7K ﹤0.01% 1539

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Cubist Systematic Strategies's CPRX Position: Q3 2024 in Review

Cubist Systematic Strategies sold out of Catalyst Pharmaceutical (CPRX) in Q3 2024, closing a stake of 8,523 shares — an estimated $132K sold.

Cubist Systematic Strategies first reported a position in CPRX in Q1 2017 and held it in 20 quarters. The position peaked at $8.23M in Q3 2022. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

  • Cubist Systematic Strategies reported no remaining Catalyst Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 8,523 Catalyst Pharmaceutical shares in Q3 2024, an estimated $132K.
  • Cubist Systematic Strategies first reported a position in Catalyst Pharmaceutical in Q1 2017 and held it in 20 quarters.
  • Cubist Systematic Strategies's Catalyst Pharmaceutical position peaked at $8.23M in Q3 2022.
  • 316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on Cubist Systematic Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.